1. Spielberg SP, Portman R. New horizons in pediatric drug development. Ther Innov Regul Sci. 2015;49:613–4.
2. McCune S, Portman RJ. Innovation and opportunities in pediatric therapeutic development. Ther Innov Regul Sci. 2019;53:564–6.
3. FDA. Rare Pediatric Disease (RPD) Designation and Voucher Programs. 2017. Rare Pediatric Disease (RPD) Designation and Voucher Programs | FDA. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-rpd-designation-and-voucher-programs. Accessed 24 Aug 2022.
4. FDA Guidance. Rare Pediatric Disease Priority Review Vouchers. 2019. Rare Pediatric Disease Priority Review Vouchers (fda.gov). https://www.fda.gov/media/90014/download. Accessed 24 Aug 2022.
5. FDA Guidance. FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act. 2021. FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act - Guidance for Industry. https://www.fda.gov/media/133440/download. Accessed 24 Aug 2022.